The role of AVP-V-2 receptor (AVP-V2R)dependent regulation of aquaporin-2 (
AQP2) expression was evaluated in vasopressin-deficient Brattleboro (BB) ra
ts. AQP2 levels were relatively high in BB rats (52 +/- 8% of levels in Wis
tar rats), and treatment with the AVP-V2R antagonist SR-121463A (0.8 mg/day
) for 48 h was associated with 1) increased urine output (170 +/- 9%), 2),
reduced AQP2 protein levels (42 +/- 10% in whole kidney and 53 +/- 8% in in
ner medulla), and 3) reduced AQP2 mRNA levels (36 +/- 7%). In addition, the
levels of AQP2 phosphorylated in the protein kinase A (PKA) consensus site
(Ser(256) of AQP2) was reduced to 3 +/- 1% of control levels. Lithium (Li)
treatment of BB rats for 1 mo, known to reduce adenylyl cyclase (AC) activ
ity, downregulated AQP2 protein levels (15 +/- 6%) and increased urine outp
ut (220%). Downregulation of AQP2 expression in response to SR-121463A or L
i treatment indicates that AQP2 expression in BB rats depends in part on ac
tivation of AVP-V(2)Rs and that the signaling cascade(s) involves AC and he
nce cAMP. Complete water restriction of BB rats produced only a small incre
ase in AQP2 mRNA (235 +/- 33%) and AQP2 protein (156 +/- 22%) levels. Immun
oelectron microscopy confirmed the increase in AQP2 abundance but revealed
no change in AQP2 apical plasma membrane labeling in response to thirsting.
In conclusion, the expression and phosphorylation of AQP2 in BB rats are i
n part dependent on AVP-V2R signaling, and AVP-V-2-mediated regulation of A
QP2 trafficking and expression is effectively decoupled in BB rats, indicat
ing differences in AVP-V2R-mediated regulation of AQP2 trafficking and expr
ession.